Found 141 results in Expert Content

Summary: In this webinar, experts provide an overview of the needs of different patient populations and examine the common challenges leading to non-compliance.

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.

This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.

Summary: Using Zydis® orally dissolving tablet (ODT) platform from Catalent as a unique delivery route for allergy immunotherapies.

Summary: Learn more about the role of oral dose delivery for tolerogenic vaccines, fast dissolving tablets and biological APIs.

Summary: While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products.

OptiForm® Solution Suite Bio is designed to rapidly screen biomolecules’ potential for a non-invasive delivery route.

Summary: Orphan drugs face obstacles that span from discovery to launch, largely because of small patient populations and limited markets for rare disease therapies.

Summary: This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets.

Summary: This webinar aims to provide clarity on the types of molecules suitable for an ODT format as well as the regulatory pathways for new and established therapies.